Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
2
0
0
CHECKMATE PHARMACEUTICALS INC
Share · US1628181083 · CMPI (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CHECKMATE PHARMACEUTICALS INC
Analyst Grade Summary
No Price
Company Profile for CHECKMATE PHARMACEUTICALS INC Share
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Company Data
Name CHECKMATE PHARMACEUTICALS INC
Company Checkmate Pharmaceuticals, Inc.
Symbol CMPI
Website
https://www.checkmatepharma.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US1628181083
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Barry A. Labinger
Country United States of America
Currency USD
Employees 0,0 T
Address 245 Main Street, 02142 Cambridge
IPO Date 2020-08-07
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | CMPI |
More Shares
Investors who hold CHECKMATE PHARMACEUTICALS INC also have the following shares in their portfolio:
